We work hard to bring you the stories about the life science community in North Carolina. Every once in a while, we add a little news of our own. Read some of those stories below, or check out some of our perspectives on our staff blog.
Last week, NCBiotech went live with a new website. As anyone who has launched a website knows, it is a long process capped by a few days of frenzied activity. We’d like to thank our partner Trone Brand Energy for dealing with us through the calm and the frenzy.
A new website really isn’t news in 2017, but our new message is worth talking about: Transformation.
A Research Triangle-based biological data analysis company founded by Duke University researchers expects to launch one spinout in about a month and another in a year to commercialize specific products it is developing.
Two panelists appearing in today’s Jobs Network program at the North Carolina Biotechnology Center will be representing one of the world’s best employers.
The U.S. Food and Drug Administration has approved ViiV Healthcare’s two-drug, once-a-day tablet combination to treat infection by a certain type of the human immunodeficiency virus (HIV).
The therapy, Juluca, consists of two previously approved drugs, dolutegravir and rilpivirine. It is the first approved HIV treatment that combines two drugs instead of three or more used in standard HIV treatment. And it's significant that it's a once-daily tablet.
